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Abstract
Tyrosine phosphorylation is a dynamic reversible post-translational modification that regulates
many aspects of cell biology. To understand how this modification controls biological function, it
is necessary to not only identify the specific sites of phosphorylation, but also to quantify how
phosphorylation levels on these sites may be altered under specific physiological conditions. Due
to its sensitivity and accuracy, mass spectrometry (MS) has widely been applied to the
identification and characterization of phosphotyrosine signaling across biological systems. In this
review we highlight the advances in both MS and phosphotyrosine enrichment methods that have
been developed to enable the identification of low level tyrosine phosphorylation events.
Computational and manual approaches to ensure confident identification of phosphopeptide
sequence and determination of phosphorylation site localization are discussed along with methods
that have been applied to the relative quantification of large numbers of phosphorylation sites.
Finally, we provide an overview of the challenges ahead as we extend these technologies to the
characterization of tyrosine phosphorylation signaling in vivo. With these latest developments in
analytical and computational techniques, it is now possible to derive biological insight from
quantitative MS-based analysis of signaling networks in vitro and in vivo. Application of these
approaches to a wide variety of biological systems will define how signal transduction regulates
cellular physiology in health and disease.
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1. The importance of tyrosine phosphorylation in cellular signaling
Cells encounter a variety of extracellular stimuli (e.g. cell-cell interactions, growth factors,
nutrients, toxins) and respond by changes in cellular function such as proliferation,
migration, differentiation, and invasion [1]. The principal mechanism for the transfer of
information from outside the cell (typically from the local environment) to inside the cell is
through phosphorylation-mediated signaling networks. Phosphorylation is one of the most
abundant post-translational modifications (PTMs) in the cell, and the phosphorylation of
serine, threonine, and tyrosine residues provides a dynamic mechanism which has the
potential to dramatically alter protein function and activation. Phosphorylation occurs most
often on serine (accounting for ~90 %), and threonine (accounting for ~10 %), with tyrosine
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phosphorylation accounting for only ~0.05 % in eukaryotic cells [2]. While there is a
complex integration of signals between serine, theronine, and tyrosine phosphorylation, here
we focus on recent advances in the identification and quantification of tyrosine
phosphorylation [3].
There are currently 90 known tyrosine kinases including 58 receptor tyrosine kinases
(RTKs) [4]. Dynamic signaling cascades are initiated by tyrosine kinase activation which is
generally triggered by extracellular ligand binding to the RTK followed by auto-
phosphorylation on conserved tyrosine residues in the intracellular portion of the receptor [5,
6]. This activation leads to the recruitment of downstream signaling molecules and
potentiation of the signal throughout the cell via networks of tyrosine phosphorylation. The
elucidation of signaling networks downstream of these RTKs is dependent on the
identification of large numbers of phosphorylation events and their quantification upon cell
perturbations with specific growth factors. Throughout these analyses it is becoming
apparent that many different RTKs employ common downstream signaling molecules to
facilitate functional changes [7]. For instance, tyrosine phosphorylation can significantly
affect protein conformation leading to changes in protein-protein interactions and
subcellular localization [8, 9]. To maintain normal cellular functions it is essential that
tyrosine kinase activities are tightly regulated. Tyrosine kinase signaling activity requires
attenuation and termination of signal transmission, and negative regulation occurs
principally through protein tyrosine phosphatases (PTPs), receptor internalization and
degradation, and negative feedback through inhibitory phosphorylation of RTKs and
associated protein kinases [10–13].
Due to its critical role in cellular homeostasis, deregulation of receptor tyrosine kinase
signaling by mutation and genetic alterations often leads to malignant transformation in
cancer. In particular, tyrosine kinases account for 0.3 % of the genome yet contribute to a
disproportionately large percentage (30 %) of the known 100 dominant oncogenes [14]. In
particular, the tyrosine kinase Bcr-Abl is deregulated in leukemia, HER-2 is amplified in
breast cancer, and EGFR, MET, and PDGFR are over-expression and mutated across a
variety of cancers [15–17]. Thus, despite the relative low levels of tyrosine phosphorylation,
it is clear that tyrosine kinases are essential in mediating cellular communication and are
critically important in the regulation of cell growth and oncogenic transformation [1, 2, 4,
18]. To facilitate the molecular characterization of tyrosine phosphorylation, it is crucial to
identify phosphorylation sites present within a cell system under specific conditions. In
addition to site localization, relative changes in phosphorylation levels upon perturbation
have an important impact on the extent of molecular change. When studying the effect of
specific components in signaling pathways, it is critical to both identify and quantify
phosphorylation sites to gain insight into the biological effects of tyrosine phosphorylation.
In this review we highlight the technical advances in mass spectrometry that have lead to the
routine identification of tyrosine phosphorylation site localization. Furthermore, we discuss
the quantitative proteomics approaches utilized for the profiling of tyrosine phosphorylation
signaling across in vitro biological systems and the challenges ahead as we extend these
technologies to the characterization of tyrosine phosphorylation signaling in vivo.
2. Phosphotyrosine enrichment
Mass spectrometry (MS) is a sensitive and specific analytical tool that has widely been
applied to the identification and characterization of PTMs across biological systems. MS
analyses typically require the separation of proteins and/or their constituent peptides, often
using chromatographic separation, prior to mass spectrometric analysis. Mass analysis of a
single purified protein can permit the assessment of the type of PTM present, such as the
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first analysis of tyrosine phosphorylation by mass spectrometry over two decades ago using
an in vitro recombinant protein [19]. However, more detailed tandem MS analysis, usually
at the peptide level, is required to enable site localization of the modification [20]. Due to
the complexity of biological systems and the distinctly low levels of tyrosine
phosphorylation, it is essential to specifically enrich for tyrosine phosphorylated proteins or
peptides, thereby drastically reducing sample complexity prior to mass spectrometric
analyses [21]. It is likely that a combination of the larger size of phosphotyrosine (compared
to phosphoserine and phosphothreonine) and the relatively low abundance has led to higher
affinity pan-specific antibodies for phosphotyrosine compared to phosphoserine or
phosphothreonine. These pan-specific high affinity anti-phosphotyrosine monoclonal
antibodies have proved to be a critical tool for the enrichment of tyrosine phosphorylation
[22]. Typically, antiphosphotyrosine antibodies are bound to phosphotyrosine proteins or
peptides and immobilized to protein agarose material prior to washing of the agarose to
remove nonspecifically bound proteins or peptides. Phosphotyrosine proteins or peptides are
then eluted from the specific antibody in a low pH solution (Fig. 1). When this strategy is
applied to enrich phosphotyrosine containing proteins, elution from the beads is typically
followed by proteolysis prior to LC-MS/MS analysis of the peptides. Unfortunately,
proteolysis of the enriched proteins generates many peptides, the vast majority of which are
non-phosphorylated. As a result, ionization of the phosphorylated peptides can be
suppressed by the non-phosphorylated peptides, and identification of the phosphorylated
peptides can be obscured, as the bulk of the instrument time is consumed by identifying
nonphosphorylated peptides. (Fig. 1) [21, 23, 24]. To obtain site specific information,
antiphosphotyrosine antibodies have more recently been used to enrich for phosphotyrosine
peptides prior to MS analysis (Fig. 1) [25, 26]. In this approach, proteins are subjected to
proteolysis using a suitable enzyme (typically trypsin) to generate peptides prior to
phosphotyrosine enrichment and liquid chromatography tandem mass spectrometry (LC-
MS/MS). Hundreds of tyrosine phosphorylation sites can be identified from complex
biological mixtures following tryptic digestion [25, 26]. Yet, it is obvious that substantial
portions of the phosphorylation sites present in the cell are missed due to tryptic fragments
that are not in the m/z range for efficient ionization and/or fragmentation by MS. This has
been identified extensively across ‘bottom-up’ proteomics and more recently numerous
proteases, such as Lys-C, Glu-C, and Asp-N, have been used to increase the overall
coverage of proteins and potential sites of modification [25]. One can envisage that the use
of these alternative proteases in the identification of phosphotyrosine sites will yield
additional and complementary information. Phosphotyrosine affinity methods are often
coupled to immobilized-metal affinity chromatography (IMAC) which allows the capture of
phosphate groups based on their interaction with the immobilized metal ion and their
negative charge [24, 26–28]. Although ferric ions immobilized on chelating resin are the
most common metal ions used for the selective enrichment of phosphorylated peptides,
multiple other metal ions have been employed, with varying degrees of specificity. IMAC
can be used as a single stage enrichment step prior to LC-MS/MS analysis to identify
phosphorylation sites in biological systems. However, due to the much greater abundance of
phosphoserine and phosphothreonine in the cell relative to phosphotyrosine, this strategy
does not typically result in the identification of large numbers of phosphotyrosine sites.
3. Tyrosine phosphorylation site localization by MS/MS
3.1 Fragmentation methods
Following enrichment for phosphotyrosine peptides, samples are analyzed by MS; site
specific information is provided by fragment ion spectra generated through tandem mass
spectrometry (MS/MS). For many years collision induced dissociation (CID) has been the
predominant method for MS/MS of peptides and proteins with and without PTMs. When
undergoing CID, peptides or proteins undergo energetic collisions with inert gas molecules,
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depositing a large amount of energy into the peptide. This energy is randomized over many
vibrational degrees of freedom before dissociation takes place at the most labile bonds,
typically resulting in fragmentation at the amide bonds along the peptide backbone. The
resulting fragment ions are predominantly b- and y-type ions containing the N- or C-
terminus of the peptide, respectively, and the series of fragment ions from a given peptide
permits the deduction of the precursor peptide sequence.
When analyzing phosphorylated peptides, identification of serine and threonine
phosphorylation sites is impeded during CID type fragmentation due to the facile cleavage
of the phosphate group, typically resulting in neutral loss of 98 Da (H3PO4) from the
precursor ion and often from the fragment ions [29, 30]. To improve fragmentation
efficiency, a neutral loss-triggered MS3 or multistage activation experiment can be
performed whereby the precursor ion mass and the neutral-loss mass (e.g. the m/z ratio of
the precursor minus the neutral loss of H3PO4) undergo fragmentation either consecutively
or simultaneously [31]. While these approaches can improve the sensitivity and potentially
the dynamic range of the MS/MS spectrum (through fragmenting the dominant neutral-loss
species), the MS/MS spectra of peptides containing serine- and threonine-phosphorylation
are typically more complex and more challenging to correctly assign as compared to MS/MS
spectra of non-modified peptides.
Tyrosine phosphorylation is largely exempt from these issues and the phosphate group
typically remains attached to b- and y-series fragment ions. In fact, in most cases, CID-based
MS/MS spectra of peptides containing tyrosine phosphorylation closely resemble the MS/
MS spectra of their non-phosphorylated analogues, with the addition of 80 Da to the
precursor and appropriate fragment ions. For this reason, CID-fragmentation is typically
used to identify the sequence and site of phosphorylation for tyrosine phosphorylated
peptides. However, some tyrosine phosphorylated peptides lose 80 Da (HPO3) from the
precursor ion, and infrequently from fragment ions, during CID, which can complicate the
MS/MS spectrum and hamper the amount of sequence information that is detected for these
peptides.
Tyrosine phosphorylated peptides can be selectively detected by MS using the specific
phosphotyrosine immonium ion at m/z 216.043 [32]. Precursor ion scanning with a
quadrupole ToF instrument was initially used to detect peptide precursor masses that
produced the m/z 216.043 immonium ion following CID; these peptide precursor masses
were then subjected to CID fragmentation to identify the sequence and site of
phosphorylation [32]. This approach works well for analysis of semi-complex mixtures; for
instance, to map sites of tyrosine phosphorylation in individual proteins. In complex
mixtures such as cell lysates, the number of tyrosine phosphorylated peptides can begin to
overwhelm this approach, and alternate strategies, including immunoaffinity enrichment of
tyrosine phosphorylated peptides, are recommended.
For data dependent MS/MS acquisition, the m/z 216.043 immonium ion can be a useful
indicator of phosphotyrosine peptides, depending on the instrument type and scan mode. If
the peptide is fragmented by CID in an ion trap (either quadrupole or linear quadrupole ion
trap), the immonium ion is often produced at fairly low levels due to the higher energy
fragmentation pathway and/or multiple fragmentation events needed to generate this ion.
Under these conditions, the immonium ion can also be lost due to the decreased stability of
ions below 30% of the selected precursor ion in ion trap instruments (note that the ‘low-
mass cutoff’ depends on the q-value; more details are available elsewhere [33]). Use of the
216.043 immonium ion to determine the presence of tyrosine phosphorylated peptides is
most common on either quadrupole TOF instruments or Orbitrap instruments, where
fragmentation is performed by higher-energy C-trap dissociation (HCD), a version of CID,
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and detection of the fragment ions occurs in the high resolution Orbitrap [29, 34]. In both of
these instruments, peptide fragmentation occurs by accelerating the precursor ion into a
collision cell filled with inert gas. The precursor ion typically undergoes a small number of
higher-energy collisions, and the resulting fragment ions are then transferred to the mass
detector, either the TOF or the Orbitrap, to generate the MS/MS spectrum. For both
instruments, while the 216.043 immonium ion indicates the presence of a tyrosine
phosphorylated peptide, not all tyrosine phosphorylated peptides produce 216.043, so the
absence of this immonium ion is not diagnostic.
Tyrosine phosphorylated peptides can also be identified by other fragmentation methods,
including electron transfer dissociation (ETD). ETD fragmentation involves the reaction of
multiply protonated precursor peptides with singly charged anions, resulting in
fragmentation at N-Cα bonds and generating c- and z- type ions [35]. This fragmentation
method has generally been applied to analysis of large peptides or intact proteins, and has
the added benefit that labile post-translational modifications are retained on the peptide,
facilitating the sequence and site identification of these PTMs. At this point in time, ETD
fragmentation is not as efficient as CID/HCD and therefore has not typically been applied to
the analysis of low-abundance tyrosine phosphorylation.
3.2 Database searching
To identify peptide sequences, MS/MS spectra are searched against a database containing
the protein sequences from the species of interest. A variety of database searching
algorithms are currently available and applicable to the identification of tyrosine
phosphorylated peptides, with the most common of these being MASCOT and SEQUEST
[36–38]. Virtually all search algorithms are based on a comparison of a theoretical (in silico)
fragment ion spectrum to the experimental MS/MS spectrum, using different comparison
and scoring metrics. For instance, SEQUEST performs a cross-correlation of theoretical and
experimental spectra, while MASCOT uses probability based scoring to determine the
likelihood of a given match. Given the comparison between experimental and theoretical
fragment ion spectra, the mass accuracy for the precursor ion and for the fragment ions is an
important factor. The precursor ion mass accuracy determines the width of the search
window; as the accuracy improves, the number of possible peptides matching the correct
mass decreases, thereby improving the likelihood of matching the correct spectra and
eliminating many potential false positives. At the limit, in the absence of PTM’s and amino
acid mutations, the mass accuracy could theoretically be sufficient to identify a peptide
sequence simply through very high mass accuracy precursor ion measurements. However, in
reality, one cannot rule out either amino acid mutations or protein PTMs, both of which will
radically expand the size of the computational protein database, leading to potentially orders
of magnitude increase in the number of possible matches within a particular search window
defined by the mass accuracy. The best solution to overcome uncertainty in the peptide
sequence assignment is to have a high quality MS/MS spectrum to accompany high mass
accuracy precursor ion measurements.
In the case of phosphotyrosine identification, enrichment is typically carried out prior to MS
analysis, thereby significantly increasing the likelihood that an identified peptide will
contain a phosphorylated tyrosine residue. However, since the analysis will generally
contain some amount of non-phosphorylated peptides and since peptides will have both
phosphorylated and non-phosphorylated tyrosines, it is necessary to search for ‘variable’
modifications, greatly increasing the size of the database, as each tyrosine has to be
considered in the phosphorylated and non-phosphorylated form when generating the
theoretical MS/MS spectra. Additionally, since some peptides are phosphorylated on nearby
serine and threonine residues (e.g. in the activation loop of many kinases), it is suggested
that variable phosphorylation of serine and threonine is also included in the database search,
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thereby increasing the search space even further. As the search space increases, the demand
on high quality MS/MS spectra also increases, due to the increased number of potential
matches to any given precursor ion match.
To increase the confidence in the identifications, it is important to understand the factors that
go into the scoring algorithm for a given database and the potential error associated with the
identifications made using a given algorithm and set of heuristics. For instance, in the
comparison of the theoretical spectrum and the experimental spectrum, as precursor ion
mass increases, the length of the peptide increases, and the number of potential fragment
ions increases. In general, the score for a given peptide match increases with the length of
the peptide, due to additional potential fragment ion matches. Thus, the threshold for ‘good’
sequence identifications should be tied to the precursor ion mass, with lower thresholds
applied to smaller peptides. To gain statistical insight into the number of potential false
positives, many groups have turned to false discovery rates (FDR), which can be calculated
for each of these algorithms. FDR calculations enable the determination of the percentage of
the total identifications that are likely false positives, where a mass spectrum is incorrectly
matched to a peptide sequence in the database. The most common method of assessing FDR
is to search the data of interest against the proper database and an alternative database
(referred to as a decoy) where the amino acid sequences are either scrambled or reversed.
The numbers of identifications that occur upon searching the decoy database are assumed to
be due to random chance as these amino acid sequences do not occur naturally in the
biological system. The ‘identifications’ resulting from the decoy database search are then
imposed onto the search results from the database containing the correct protein sequences,
and the number of false positives, and therefore the FDR rate, can be calculated [39]. There
are several assumptions and flaws in this approach, and FDR calculations based on
commonly used decoy databases dramatically under represent the true percentage of
incorrect identifications [40]. Even if the FDR were accurate, this approach only provides an
estimate of the number of potential false positives, and does not identify the spectra that may
be incorrectly assigned.
3.3 Phosphorylation site determination
Once the peptide sequence has been accurately determined, the next challenge is to localize
the site of phosphorylation. While some peptides have only a single modifiable residue, the
majority of peptides have multiple potential sites of modification (serines, threonines, and
tyrosines). In these cases, search algorithms are often not able to accurately determine the
site of modification, and in fact, accurate site localization by MS can be non–trivial, as
confident localization of phosphorylation requires the presence of specific fragment ions
flanking the modified amino acid.
Accurate site localization is essential for biological insight, as the sequence motif
surrounding the phosphorylation site can be used to suggest the identity of the kinase that
may have phosphorylated the site. Perhaps more importantly, functional validation of the
phosphorylation site is often performed through mutation of the modified site to either a
non-phosphorylatable analogue (e.g. phosphotyrosine to phenylalanine) or a
phosphomimetic residue (e.g. phosphotyrosine to glutamine); in these cases knowing the
exact site of modification is absolutely critical, especially given the effort necessary to
perform each mutation and test the resulting phenotypic effect. At a larger scale, there is a
significant proportion of phosphorylation site data that is catalogued in online databases
such as phosphosite (www.phosphosite.org/) and phosida (www.phosida.de/). In many cases
the error associated with modification site localization determinations are not typically taken
into consideration on curation of these large-scale databases [41]. Site localization errors
then can be propagated when these large scale databases are queried for phosphorylation
motifs, for structural insights, and for evolutionary conservation of phosphorylation.
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Therefore, the error associated with incorrect site localization has the potential to affect not
only single experiments, but also large-scale bioinformatic studies.
The need for more accurate site identification has led to the development of software
methods aimed at calculating the confidence in phosphorylation site assignments of each
serine, threonine, and tyrosine residue present within a peptide sequence. As one example,
the post translational modification (PTM) scoring tool in the MSQuant software calculates
theoretical spectra for all possible phosphorylated versions of each peptide. The algorithm
then assigns the most intense ions per 100 m/z in each fragmentation spectrum and
calculates the best match [42]. As an alternative, the Ascore algorithm
(ascore.med.harvard.edu/) calculates probability scores for each phosphorylation site
localization, with the most likely site determined based on the presence and intensity of site-
specific fragment ions [43]. Finally, the MASCOT delta score is a commonly used and
easily applied approach [44]. When routinely searching phosphorylation data a score is
calculated for all different possible phosphorylation sites on a phosphopeptide. As the
phosphorylation site with the highest score is the most likely to be correct, this method
calculates the difference between the top scoring phosphorylation site and those alternate
sites with lower scores. Confidence in site assignment therefore increases with increasing
differential between the top site and the next highest score [44].
3.4 Manual Validation
Despite the latest developments, all phosphorylation site localization and peptide
identification algorithms have an associated error that cannot be accurately calculated [40].
This error is further compounded by the fact that almost all phosphorylation site
identifications are ’one-hit wonders’, where the identification of the site is based on a single
(or multiple replicate) MS/MS spectrum. Since sequence and site identification is critical for
biological insight, manual validation of tyrosine phosphorylation sites is strongly
recommended [45]. The aim of manual sequence validation is to assign fragment ions that
are indicative of the full peptide sequence, and if possible, to identify all of the fragment
ions that are present in the MS/MS spectra [45]. It is worth noting that peptides may
fragment in an unpredictable way, making it difficult to identify all of the fragment ions that
are present within a MS/MS spectrum. In this case, to definitively identify peptides and
phosphorylation sites a long standing option has been the generation of chemically
synthesized phosphorylated peptides matching the identified sequence from the biological
sample. The MS/MS spectrum of the synthetic phosphopeptide can then be compared to the
original MS/MS spectrum to confirm the putative identification. In selected cases, coelution
or MS3 experiments can also be performed to further strengthen the confidence in the
identification [46]. Manual validation is manageable for data sets comprised of hundreds of
phosphorylation sites, but as the scan speed and sensitivity of the instrumentation improves,
the number of phosphorylation sites that are routinely identified continues to increase,
making manual validation more challenging. To address this challenge, we have developed a
computational approach, based on manually validated spectra, that automatically removes
many of the false-positive identifications from the searching algorithm [47]. Moving
forward it is vital to pursue a more rigorous approach that combines software and manual
validation to understand the biological importance of identified phosphorylation sites.
4. Quantitative analyses
Protein tyrosine kinases and phosphatases regulate physiological events at a molecular scale
by altering the level of phosphorylation at selected sites on given proteins, thereby affecting
protein function, protein-protein interaction, and potentially protein stability. To properly
decipher these events, in addition to sequence and site identification, quantitative
information, either relative or absolute, regarding the level of phosphorylation under
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different conditions is required. Relative quantification of phosphorylation can be carried
out as an extension of the enrichment of phosphotyrosine peptides (Fig.1).
Although there are variations in the labeling agents used and the stage in the analytical
workflow at which the analyte is labeled, quantification of phosphotyrosine generally
consists of two or more samples being differentially labeled and combined prior to mass
spectrometric analysis. Numerous methods are available for stable isotope labeling for
quantitative analysis using mass spectrometry. These methods fall broadly into two
categories: metabolic labeling, where proteins are labeled with stable isotopes during cell
culture, and chemical labeling, where proteins or peptides derived from complex biological
samples are differentially labeled with stable isotopes or mass tags using chemical reactions,
typically after cell lysis (Fig. 2). The most widely applied variation of metabolic labeling is
stable isotope labeling in cell culture (SILAC) [23]. During SILAC, cells are grown in the
presence of isotopically labeled amino acids. 13C6-arginine and 13C6-lysine are commonly
used to introduce a consistent mass difference in all tryptic peptides, with addition of 15N to
these amino acids enabling comparison of three samples. In this case, the ‘light’ samples are
unlabeled, ‘medium’ peptides are labeled with 13C6-arginine and 13C6-lysine, and ‘heavy’
peptides are labeled with 13C615N4-arginine and 13C615N2-lysine. MS analysis of ‘medium’
or ‘heavy’ labeled samples combined with samples from unlabeled cells provides accurate
quantification based on relative intensities of precursor peptide ions derived from each
sample, with each peptide mass differing by the number or arginines or lysines in the
peptide sequence (Fig. 2). The clear benefit of this methodology is that it allows the labeling
of large amounts of protein, thus allowing the use of a large amount of starting material to
circumvent sensitivity limitations. Furthermore, as the samples can be combined much
earlier in the sample preparation workflow, (i.e. cell lysates can be combined directly with
each other) there is minimal variation associated with slight differences in processing of the
various samples. Although initially limited to cell culture, SILAC labeling of whole
organisms has been developed through application of an exclusive diet of 13C6-substituted
versions of amino acids over multiple generations [48, 49]. Full incorporation of stable
isotopically labeled amino acids is achievable, but the prohibitively high cost of the diet
coupled to the extensive time required for complete labeling limits the application of in vivo
SILAC.
Chemical tagging strategies provide a useful and accurate alternative to metabolic labeling.
There are multiple available strategies for the chemical labeling of proteins and peptides,
ranging from simple acetylation or methylation reagents to more complex, multiplexed
options such as isobaric tags for relative and absolute quantification (iTRAQ) and tandem
mass tags (TMT). Currently, iTRAQ quantification is the most common method applied to
the quantitative analysis of phosphotyrosine; using this approach it is now possible to
quantify up to 8 independent samples within a single experiment. iTRAQ labeling consists
of differential labeling of peptides through the reaction of an isobaric mass tag with all free
ε-amine groups present in the sample, namely the N-terminus of a peptide chain and lysine
side chains. The iTRAQ labels are isobaric and co-elute chromatographically, thus peptides
labeled with the different iTRAQ isoforms elute as a single peak (with associated isotope
envelope) in the MS spectrum. However, upon fragmentation (CID, HCD) the iTRAQ
moiety dissociates, producing characteristic fragment ions of m/z 114–117 for 4plex iTRAQ
and m/z 113–121 for 8 plex iTRAQ (discounting 120 due to the presence of the
phenylalanine immonium ion) in the MS/MS spectrum. The relative intensities of each of
these reporter ions enable relative determination of peptide or phosphorylation levels in the
respective biological samples (Fig. 2). This quantification strategy has been used to quantify
tyrosine phosphorylation signaling networks with site-specific resolution in a variety of
different biological applications. For instance, we have used this approach to generate
temporal dynamic profiles of tyrosine phosphorylation sites from cells stimulated with EGF
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[26], insulin [50], or anti-CD3 to stimulate the T-cell receptor [51]. We have also used
iTRAQ to characterize signaling networks and study the effects of point mutations in
EGFRvIII expressing glioma cell lines [52, 53]. Since iTRAQ labeling occurs post-lysis, this
technique is generally applicable to all biological samples, including direct comparisons of
human tissues. However, the total amount of biological material that can be labeled and
analyzed in a single experiment is limited by the reagent cost, and thus the MS sensitivity
required to comprehensively characterize and quantify tyrosine phosphorylation signaling is
significantly increased.
5. Reproducibility: ‘Discovery’ and ‘Targeted’ approaches
Many of the tyrosine phosphorylation site identifications are carried out using data
dependent acquisition (DDA) experiments, in which the top n-most (typically n = 5–20)
abundant ions from the full scan mass spectrum (MS1 scan) are isolated and subjected to
MS/MS. Unfortunately, due to variability in the timing of selection, isolation, and
fragmentation between separate analyses, the reproducibility of peptide and phosphorylation
site identification between analyses tends to be poor. We have previously shown that the
experimental reproducibility of DDA experiments is 34% across four replicate analyses for
iTRAQ-based quantification of temporal tyrosine dynamics following EGFR stimulation
[54]. While iTRAQ multiplexing improves the reproducibility (e.g. through identification
and quantification of 4 or 8 samples in a single analysis), comparison across multiple
iTRAQ-based MS analyses still faces these same issues. With this poor reproducibility, it
becomes challenging to get quantification for every phosphorylation site across multiple
biological replicates. To address this issue, we have previously applied multiple reaction
monitoring (MRM) to quantify tyrosine phosphorylation using a triple quadrupole
instrument. In MRM, the first quadrupole isolates a precursor ion with a particular m/z
which is then fragmented in the collision cell (second quadrupole), while the third
quadrupole is set to pass only selected fragment ions. In this way, only peptide precursor and
fragment ions of the correct mass (m/z ratio) are detected, and the instrument can spend
additional time targeting these selected transitions. Due to the increased sensitivity of
identification and quantification associated with increased detection time for the selected
transitions, MRM is often used for quantification of low-level species in biological matrices.
Since this approach is targeted to quantify particular peptides and fragment ions, a priori
knowledge such as chromatographic elution time, m/z ratios of peptide precursor ions and
m/z ratios of characteristic fragments generated during MS/MS are required. In general, one
or more ‘discovery-mode’ DDA analyses are performed to generate the list which is then
imported into the MRM method for targeted quantification across multiple replicates or
different conditions. In one application, phosphorylated peptides identified from two iTRAQ
DDA experiments were collated to construct a tailormade MRM method to quantify over
200 tyrosine phosphorylation sites [54]. Using this approach the inter-experimental
reproducibility across four replicate analyses increased to 88%, thereby enabling the
multiplexed analysis of two iTRAQ experiments reflecting seven different time points in an
EGF time course [54]. With the increased speed of the latest generation of mass
spectrometers, it should now be possible to generate full-scan MS/MS spectra for a large list
of precursor peptide targets, improving the MRM approach through the acquisition of high-
resolution fragment ion spectra and thereby decreasing false-positive or contaminated MRM
data.
6. Biological Insight from Informatics
Once tyrosine phosphorylation sites have been identified and quantified, the next challenge
is to gain biological insight from these complex quantitative data sets. To this end, multiple
bioinformatics approaches have been developed to extract information from well-
Johnson and White Page 9
Semin Cell Dev Biol. Author manuscript; available in PMC 2013 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
characterized sites with the goal of inferring putative function for poorly characterized
proteins and phosphorylation sites. In two different studies, we have applied clustering
methods to distinguish subgroups of phosphorylation sites based on quantitative
phosphorylation profiles to generate hypotheses for further functional validation [26, 52]. To
further interrogate phosphorylation data, we have developed PTMscout (ptmscout.mit.edu/)
as an on-line repository enabling the comparison of data to previously identified sites [55].
PTMscout enables the generation of PTM motifs that may be present within the dataset of
interest, generates gene ontology annotations, and applies Scansite predictions
(scansite.mit.edu/) [56] to identify kinases that may be responsible for the phosphorylation
of each identified phosphorylation site. To gain additional insight into the connection
between signaling and cell physiology bioinformatics methods can be used correlate
quantitative cell based phenotypic measurements (i.e. cell migration and proliferation) with
phosphorylation data gathered under the same conditions [54]. For example, partial least
squares regression (PLSR) modeling enabled the identification of nine tyrosine
phosphorylation sites on six proteins whose temporal dynamic measurements provided
sufficient information to predict cell invasion and migration in HER2 over-expressing
human mammary epithelial cells (HMECs) [57, 58]. PLSR also enables the assignment of
putative functions to novel phosphorylation sites, and provides quantitative predictions for
the effect of deleting or inhibiting selected phosphorylation sites. Although PLSR has
predominantly been applied to analysis of signaling and phenotype of cells in culture, it is
also possible to apply this technique to cells and tissues in vivo, providing that quantitative
phenotypic data is available for these tissues.
7. Characterization of tyrosine phosphorylation signaling events in vivo
The majority of phosphotyrosine analyses have been carried out using in vitro model
systems, most likely due to the ease of generating the large sample amounts associated with
isolation and characterization of low-abundance tyrosine phosphorylation sites. Despite
many insights gained from studying these in vitro model systems, the role of tyrosine
phosphorylation in the pathogenesis of multiple diseases, including many cancers, has
highlighted the need for comprehensive analyses of tyrosine phosphorylation across disease
states in vivo to enable the relevant identification of new drug targets. Tyrosine kinases and
phosphatases have been identified to be deregulated across many cancer types through
genetic profiling, leading to the development of single agent kinase inhibitors. Although
tumors initially respond to treatment with these single agent inhibitors, these treatments are
often not curative and these tumors eventually become resistant to these kinase specific
drugs. It is thought that resistance may be due to the presence of tumor heterogeneity and
tumor-stroma interactions in the tumor microenvironment, both of which are virtually
impossible to recapitulate in an in vitro cell system. To fully understand the relevance and
regulation of tyrosine phosphorylation in the context of human cancer pathogenesis, it is
essential to move towards the analysis of patient tumors.
As one transitions from in vitro to in vivo analysis of tyrosine phosphorylation, sample
procurement and processing becomes a critical factor. Due to the rapid signaling response to
hypoxia and stress, it is essential to freeze the tissue within seconds to minutes of resection
when characterizing physiological phosphorylation. However, samples that are routinely
stored in tissue repositories are often not frozen within this time-frame; in many cases the
delay between resection and freezing is not documented. Regardless, there have recently
been a few attempts at semi-quantitative profiling of tyrosine phosphorylation sites across in
vivo model systems and patient tumor tissues [59, 60]. The largest of these studies was a
phosphotyrosine profiling screen which was carried out across 41 non-small cell lung cancer
(NSCLC) cell lines and 150 NSCLC tumors [59]. In this study a total of 4500
phosphotyrosine sites were identified on more than 2700 proteins, a truly astounding number
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[59]. Semi-quantitative label-free analysis was used to quantify tyrosine phosphorylated
peptides and the resulting tyrosine kinase profiles were then clustered to reveal distinct
groups of tumors [59, 60]. While these results were intriguing, it is worth noting that label-
free quantification requires reproducible sample processing and chromatographic separation
of peptides prior to MS analysis. Although this technique has been applied to the
quantification of proteins from complex samples with modest success [61], it cannot be
applied accurately to the quantification of PTMs due to the enrichment methods that are
typically required prior to MS analysis. Enrichment steps introduce an additional level of
variation based on a complex number of variables, including sample concentrations,
incubation times, antibody amounts, batch-to-batch variation in antibody quality, and
irreproducibility in non-comprehensive immunoprecipitations. Furthermore, tyrosine
phosphorylation occurs at low abundance, and therefore there are typically only a few MS/
MS events per peptide, representing a regime in which spectral counting approaches, in
which the quantification is based on the number of MS/MS spectra, are notoriously poor.
Moving forward, it is essential that rigorous methods of quantification are applied to the
characterization of tissue samples. Coupling isotopic labeling strategies to targeted MS
based approaches will help increase sample to sample reproducibility when attempting to
profile large numbers of in vivo tissue samples. In addition to improving quantification and
reproducibility, we must also increase our confidence in phosphorylation site identification
through extensive manual and computational validation of MS data. Finally, improved
bioinformatic and computational modeling tools are needed to provide the framework to
understand the vastly different functional roles of tyrosine phosphorylation. In the near
future, the rigorous application of these tools and techniques to quantify signaling networks
in biological samples will reveal critical insights into the regulation and deregulation of in
vivo signaling networks in health and disease.
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Abbreviations
CID collision induced dissociation
DDA Data dependent acquisition
ETD Electron transfer dissociation
FDR False discovery rate
HMEC Human mammary epithelial cells
iTRAQ isobaric tags for relative and absolute quantification
MRM Multiple reaction monitoring
MS Mass spectrometry
MS/MS tandem mass spectrometry
PLSR Partial least square regression
PTM post-translational modification
PTP Protein tyrosine phosphatase
RTK receptor tyrosine kinase
SILAC stable isotope labeling in cell culture
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Highlights
In this review, we highlight the critical issues that need to be addressed as mass
spectrometry based analysis of tyrosine phosphorylation signaling moves from in vitro
samples to the in vivo setting.
We provide background information regarding the various technologies underlying
quantitative analysis of tyrosine phosphorylation by mass spectrometry
We discuss the application of isotopic labeling strategies for quantitative mass
spectrometry of in vitro and in vivo samples
The importance of site specific identification and the challenges underlying automated
site identification are highlighted, along with the need for manual validation of at least
the most biologically relevant phosphorylation sites
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Fig. 1.
Tyrosine phosphorylation enrichment prior to MS analysis. The most common methods of
tyrosine phosphorylation enrichment are peptide enrichment (left) and protein enrichment
(right). Protein enrichment consists of cell or tissue lysis followed by protein IP using anti-
phosphotyrosine antibodies. Proteins are then digested into peptides using trypsin (or other
suitable proteases) and analyzed by LC-MS/MS. Using this approach; proteins are
identified, along with some phosphorylation sites. Peptide enrichment consists of cell or
tissue lysis followed by digestion with trypsin (or other suitable proteases) and peptide IP
using anti-phosphotyrosine antibodies. Tyrosine phosphorylated peptides are subsequently
analyzed by LC-MS/MS. Peptides from both approaches are searched against a relevant
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sequence database using a search algorithm. The bottom panel shows the tyrosine
phosphorylated peptide IQNTGDYYDLYGGEK which has 3 tyrosine residues that could be
phosphorylated (indicated by arrows). Manual validation leads to the unequivocal
identification of Y7 as the phosphorylation residue by the assignment of a, b and y series
fragment ions.
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Fig. 2.
Relative quantification of tyrosine phosphorylation by mass spectrometry. Metabolic
labeling and chemical labeling are routinely applied to in vitro quantitative analyses while
chemical labeling is the most common quantitative strategy for in vivo quantification (as
indicated by the arrows). During SILAC, cells from up to three different conditions are
cultured in different SILAC-labeled media (either unlabeled; Lys0, Arg0, labeled with 13C6-
arginine and 13C6-lysine; Lys6, Arg6 or labeled with 13C615N4-arginine and 13C615N2-
lysine; Lys8, Arg10). Cell lysates are combined, proteolyzed to peptides and subjected to a
phosphotyrosine IP to enrich for phosphotyrosine peptides prior to analysis by LC–MS/MS.
SILAC quantification data is dependent on the integration of MS peak intensities or
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chromatographic peak area for differentially labeled peptides. For iTRAQ labeling, up to
eight biological samples are lysed in detergent or chaotropic agents; proteins are proteolyzed
to peptides and tryptic peptides from individual samples are differentially labeled with
isobaric mass tags. Labeled samples are then combined and analyzed by LC–MS/MS.
Peptide quantification is determined by comparison of iTRAQ reporter ion intensities (m/z
113–121). Peptide identification is determined by the MS/MS spectrum in both approaches.
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